Search hospitals > Michigan > Chelsea
Saint Joseph Mercy Chelsea
Claim this profileChelsea, Michigan 48118
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Breast cancer
Conducts research for Cancer
Conducts research for Non-Small Cell Lung Cancer
223 reported clinical trials
7 medical researchers
Summary
Saint Joseph Mercy Chelsea is a medical facility located in Chelsea, Michigan. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Cancer, Non-Small Cell Lung Cancer and other specialties. Saint Joseph Mercy Chelsea is involved with conducting 223 clinical trials across 329 conditions. There are 7 research doctors associated with this hospital, such as Tareq Al Baghdadi, Christopher M. Reynolds, MD, Philip J. Stella, and Elie G. Dib.Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage II
Stage III
2Breast Cancer
Global LeaderHER2 negative
Stage IV
ER positive
Top PIs
Tareq Al BaghdadiGenesys Hurley Cancer Institute8 years of reported clinical research
Expert in Cancer
Expert in Pancreatic Cancer
73 reported clinical trials
130 drugs studied
Christopher M. Reynolds, MDSaint Joseph Mercy Hospital2 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
51 reported clinical trials
104 drugs studied
Philip J. StellaSaint Joseph Mercy Hospital5 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
38 reported clinical trials
89 drugs studied
Elie G. DibGenesys Hurley Cancer Institute6 years of reported clinical research
Studies Multiple Myeloma
Studies Breast Cancer
38 reported clinical trials
105 drugs studied
Clinical Trials running at Saint Joseph Mercy Chelsea
Lung Cancer
Breast Cancer
Esophageal cancer
Cancer
Ovarian Cancer
Breast cancer
Prostate Cancer
Multiple Myeloma
Bladder Cancer
Gastric cancer
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Stereotactic Radiosurgery vs Whole-Brain Radiotherapy
for Brain Metastasis from Lung Cancer
This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer that has spread to the brain. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Whole brain radiation therapy delivers a low dose of radiation to the entire brain including the normal brain tissue. Hippocampal avoidance during whole-brain radiation therapy (HA-WBRT) decreases the amount of radiation that is delivered to the hippocampus which is a brain structure that is important for memory. The drug, memantine, is also often given with whole brain radiotherapy because it may decrease the risk of side effects related to thinking and memory. Stereotactic radiosurgery may decrease side effects related to memory and thinking compared to standard of care HA-WBRT plus memantine.
Recruiting2 awards Phase 315 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Saint Joseph Mercy Chelsea?
Saint Joseph Mercy Chelsea is a medical facility located in Chelsea, Michigan. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Cancer, Non-Small Cell Lung Cancer and other specialties. Saint Joseph Mercy Chelsea is involved with conducting 223 clinical trials across 329 conditions. There are 7 research doctors associated with this hospital, such as Tareq Al Baghdadi, Christopher M. Reynolds, MD, Philip J. Stella, and Elie G. Dib.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.